Table 1 Baseline characteristics of patients of hepatocellular carcinoma undergoing radiofrequency ablation (RFA).
Variables | Patients (n = 499) |
|---|---|
Age (years, median [interquartile range]) | 67 [58–76] |
Male, n (%) | 326 (65) |
Etiologies of liver disease | |
HBV, n (%) | 183 (37) |
HCV, n (%) | 160 (32) |
HBV + HCV, n (%) | 19 (4) |
Alcohol, n (%) | 81 (16) |
Others, n (%) | 75 (15) |
aDiabetes mellitus, n (%) | 143 (29) |
Performance status (0/1/2-3), n (%) | 370/76/53 (74/15/11) |
Ascites, n (%) | 69 (14) |
Alpha-fetoprotein(ng/ml, median, [interquartile range]) | 18.24 [6.93–67.67] |
Laboratory values (mean ± SD) | |
Alanine aminotransferase (IU/L) | 64.47 ± 55.04 |
Aspartate aminotransferase (IU/L) | 64.46 ± 52.88 |
aAlkaline phosphatase (IU/L) | 107.97 ± 78.85 |
Albumin (g/dl) | 3.75 ± 0.6 |
Total bilirubin (mg/dl) | 1.08 ± 1.06 |
Creatinine (mg/dl) | 1.184 ± 1.154 |
Platelets (1,000/μL) | 125.54 ± 62.13 |
INR of prothrombin time | 1.09 ± 0.14 |
Non-invasive liver function models | |
ALBI grade (1/2/3), n (%) | 209/261/29 (42/52/6) |
APRI grade (1/2/3), n (%) | 122/205/172(24/41/35) |
CTP classification (A/B/C), n (%) | 413/76/10 (83/15/2) |
CDS grade (1/2/3), n (%) | 78/320/101 (16/64/20) |
FIB-4 grade (1/2/3), n (%) | 37/138/324 (7/28/65) |
GUCI grade (1/2/3), n (%) | 119/199/181 (24/30/46) |
Lok index grade (1/2/3), n (%) | 204/196/99 (41/39/20) |
MELD score (1/2/3), n (%) | 217/197/85 (43/40/17) |
PALBI grade (1/2/3), n (%) | 273/157/69 (55/31/14) |
King’s score (1/2/3), n (%) | 31/112/356 (6/22/72) |
Tumor nodules (1/2/ ≥ 3), n (%) | 384/79/36 (77/16/7) |
Maximal tumor diameter (≤2/2-3/>3 cm), n (%) | 206/172/121 (41/35/24) |
TTV (ml, median, [interquartile range]) | 7.24 [2.57–16.25] |
